Axon Enterprise (NASDAQ:AXON) Stock Rating Lowered by Northcoast Research

Northcoast Research cut shares of Axon Enterprise (NASDAQ:AXON) from a buy rating to a neutral rating in a research note released on Wednesday, MarketBeat.com reports.

A number of other equities analysts have also recently weighed in on the company. Northland Securities upped their price target on Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. Morgan Stanley raised shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $500.00 to $700.00 in a research report on Tuesday, December 3rd. Needham & Company LLC raised their price target on shares of Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Robert W. Baird boosted their target price on shares of Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research report on Friday, December 6th. Finally, JMP Securities boosted their target price on shares of Axon Enterprise from $610.00 to $725.00 and gave the stock a “market outperform” rating in a research report on Tuesday, February 4th. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $561.31.

Axon Enterprise Stock Down 5.3 %

NASDAQ AXON opened at $513.22 on Wednesday. The stock has a market cap of $39.13 billion, a PE ratio of 132.62, a P/E/G ratio of 5.95 and a beta of 1.05. Axon Enterprise has a fifty-two week low of $265.32 and a fifty-two week high of $715.99. The business has a 50 day moving average price of $619.94 and a two-hundred day moving average price of $517.11. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32.

Insider Activity at Axon Enterprise

In related news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $604.07, for a total transaction of $271,831.50. Following the completion of the sale, the director now owns 6,929 shares of the company’s stock, valued at $4,185,601.03. This represents a 6.10 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jeffrey C. Kunins sold 2,304 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $654.79, for a total transaction of $1,508,636.16. Following the transaction, the insider now directly owns 128,542 shares of the company’s stock, valued at $84,168,016.18. The trade was a 1.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 8,711 shares of company stock valued at $5,631,561 in the last quarter. Insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Fourth Dimension Wealth LLC acquired a new position in Axon Enterprise during the 4th quarter valued at about $30,000. Prestige Wealth Management Group LLC boosted its stake in Axon Enterprise by 115.8% during the 3rd quarter. Prestige Wealth Management Group LLC now owns 82 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 44 shares during the period. New Wave Wealth Advisors LLC acquired a new position in Axon Enterprise during the 4th quarter valued at about $40,000. Brooklyn Investment Group acquired a new position in Axon Enterprise during the 3rd quarter valued at about $41,000. Finally, Y.D. More Investments Ltd acquired a new position in Axon Enterprise during the 4th quarter valued at about $45,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.